S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

How a Fast Track Designation Saved Corbus Pharma

Photo of Chris Lange
By Chris Lange Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

fda_logo
Wikimedia Commons
Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) made a quiet entrance into the market last November in its initial public offering that priced for $3.00. Since then Corbus has had a rough time as shares are down 37.8% year to date (as of Tuesday’s close $1.86) and just above their 52-week lows. However the company may have found its saving grace in a Fast Track designation from the U.S. Food and Drug Administration (FDA).

The company announced Wednesday morning that the FDA designated as a Fast Track development program the investigation of Resunab for systemic sclerosis.

For some background: systemic sclerosis is a serious, life-threatening autoimmune disease that is characterized by chronic activation of the immune system, damage to blood vessels and fibrosis (scarring) of the skin, lungs and other internal organs. The candidate Resunab is a novel synthetic oral endocannabinoid-mimic drug that preferentially binds to a receptor called CB2 on immune cells and fibroblasts.

The Fast Track designation will allow for more frequent interactions with the FDA in an effort to expedite the development and review process for drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical need.

Corbus CEO Yuval Cohen, Ph.D., stated:

We are very pleased to have achieved another significant regulatory milestone for Resunab for the treatment of systemic sclerosis, following the recently granted FDA Orphan Drug Designation in this indication. With Fast Track status, we expect to have the opportunity to accelerate Resunab’s clinical development timeline to more expediently bring this potentially impactful drug therapy to individuals with systemic sclerosis.

Shares of Corbus were up over 100% at $3.87 Wednesday morning. The stock has a post-IPO trading range of $1.80 to $4.95. More than 29 million shares had moved as of 11:00 a.m. Eastern compared to the average daily volume of 131,000.

ALSO READ: 4 Top Pharma Stocks That Should Outperform Out to 2016

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Chris Lange |

Corbus Wins With FDA Fast Track Designation

Corbus Pharmaceuticals announced that the FDA has designated as a Fast Track development program and granted Orphan Drug Designation to…
Chris Lange |

What Lit a Fire Under These 3 Pharma Stocks

Over the past week, a few pharmaceutical companies made absolutely massive runs.
Corbus Pharma Suffers Big Setback in Systemic Sclerosis Study
Chris Lange |

Corbus Pharma Suffers Big Setback in Systemic Sclerosis Study

Corbus Pharmaceuticals has reported that its systemic sclerosis study failed to reach the endpoints, and investors were not pleased.
Corbus Pharmaceuticals Skyrockets on Positive Mid-Stage Results
Chris Lange |

Corbus Pharmaceuticals Skyrockets on Positive Mid-Stage Results

Corbus Pharmaceuticals shares skyrocketed on Monday morning after the company announced positive results from its mid-stage clinical trial in systemic…
cgblaine22 |

Peregrine Move Looks Sustainable, at Least for Now

Peregrine Pharmaceuticals may be on the verge of something big with its anticancer drugs. The shares soared almost 50% on…
3 Stocks With Catalysts That Could Capitalize on Biotech Momentum
Trey Thoelcke |

3 Stocks With Catalysts That Could Capitalize on Biotech Momentum

If the momentum in biotech can continue, then companies with catalysts within the next 12 to 18 months could get…
Proteostasis Therapeutics Wins Big With FDA Decision
Chris Lange |

Proteostasis Therapeutics Wins Big With FDA Decision

Proteostasis Therapeutics shares made a solid gain on Wednesday after a key FDA decision was announced.
aTyr Receives FDA Fast Track Designation
Chris Lange |

aTyr Receives FDA Fast Track Designation

aTyr Pharma watched its shares climb early on Monday after the company announced that its product candidate Resolaris was granted…
Could This Be a Turning Point for Fate Therapeutics?
Chris Lange |

Could This Be a Turning Point for Fate Therapeutics?

Shares of Fate Therapeutics saw a healthy gain early on Monday following a key U.S. Food and Drug Administration (FDA)…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618